Latest Industry News & Trends
Market Scope provides comprehensive coverage of the ophthalmic market. Our news stories are a combination of public and proprietary content ranging from coverage of international meetings, surgeon survey results and trends, analysis of company financial reports and public medical registries, press releases, and interviews with executives. Register today to receive free weekly email updates, our top data chart, surgeon poll results, and much more. Locked content can be accessed through a subscription to our ophthalmic industry newsletters.
Recently Added News
Nearly 76 Thousand Cases of Ocular Lubricants Recalled, US FDA Alert Says
The US FDA issued alerts recently regarding the recalls of five ocular lubricant products and one generic glaucoma medication. BRS Analytical Services, a contract testing laboratory based in St. Lo...
Intalight Receives CE Marking for Dream OCT Swept Source Imaging
Ophthalmic diagnostic company Intalight announced May 15 that it had received CE marking for its Dream optical coherence tomography (OCT) platform. Intalight, with offices in San Jose, California, ...
Bausch + Lomb Receives CE Marking for Preloaded LuxLife Trifocal IOL
Bausch + Lomb announced May 7 that the LuxLife trifocal intraocular lens (IOL) had received CE marking in Europe. The company said the nondiffractive LuxLife has an uninterrupted, continuous refrac...
Q1-2025 Ophthalmic Revenue Roundup for Alcon, Immunocore, Harrow, Sight Sciences, ANI, Iridex, and Xbrane
Alcon reported May 13 that its Q1-2025 net sales were $2.45 billion, on par with $2.44 billion in Q1-2024 and up 3 percent on a constant currency basis. Surgical net sales totaled $1.33 billion (do...
Lenz Licenses Presbyopia Drop Candidate to Lotus Pharmaceutical for Korea, Southeast Asia
Lenz Therapeutics announced May 9 a license agreement with Taiwan’s Lotus Pharmaceutical for exclusive rights to market LNZ100 (1.75% aceclidine) for presbyopia in South Korea and certain countries...
US FDA Grants Breakthrough Status to Viridian’s Thyroid Eye Disease Candidate
Viridian Therapeutics announced May 7 that the US FDA had granted breakthrough therapy status to veligrotug, the company’s anti-insulin-like growth factor-1 receptor (IGF-1R) candidate for thyroid ...
Unity Bio to Cut Workforce, Seek Strategic Alternatives for UBX1325 in Retina
Unity Biotechnology announced May 5 that it would reduce its workforce and seek an established ophthalmic company to continue the development of UBX1325, a Tie2/anti-VEGF bispecific antibody candid...
Maximilian Foerst to Lead Carl Zeiss Meditec, as Markus Weber, PhD, Steps Down
Carl Zeiss Meditec announced May 7 that Markus Weber, PhD, the company’s president and CEO, will step down of his own accord, effective May 31. Replacing Weber will be Maximilian Foerst, currently ...
TME Pharma to Expand Cost-Cutting, Nominate New CEO
Germany’s TME Pharma, a clinical-stage cancer company, announced May 5 that it would expand its cost-cutting measures by outsourcing staffing and nominate Diede van den Ouden for appointment as CEO...
Topcon Healthcare Acquires RetInSight to Advance AI-Powered Imaging in Eye Care
Topcon Healthcare announced May 2 that it had acquired privately held retinal AI analysis company RetInSight, of Austria. No financial details were disclosed. The companies forged a partnership in ...
Q1-2025 Ophthalmic Revenue Roundup for Amgen, Hoya, Apellis, Tarsus, STAAR, RxSight, and Ocular Therapeutix
Amgen, of Thousand Oaks, California, reported May 1 that its Q1-2025 revenue from Tepezza was $381 million, a 10 percent decrease from $424 million in Q1-2024. The total consisted of $365 million...
Elanco Sells US Royalty and Milestone Rights for Xdemvy to Blackstone for $295 Million
Elanco, of Greenfield, Indiana, announced May 5 that it had sold certain future US tiered royalties and commercial milestone payments associated with Tarsus’ Xdemvy (lotilaner ophthalmic solution 0...
Past News Stories
Okyo Pharma Accelerates Development of Urcosimod in Neuropathic Corneal Pain
London’s Okyo Pharma announced April 30 that it would accelerate development of urcosimod, formerly OK-101, in neuropathic corneal pain, following early closure of its Phase II trial. The trial was...
US FDA Grants Marketing Clearance for OcuSciences’ OcuMet Beacon Retinal Imager
OcuSciences, of Ann Arbor, Michigan, announced May 1 that the US FDA had granted marketing clearance for its flagship device, the OcuMet Beacon retinal imager. The 510(k) clearance describes the Oc...
RetinAI and FVS Gain CE Marking for LuxIA DR Screening Algorithm
Switzerland’s RetinAI and Spain’s Fundación Ver Salud (FVS) announced April 30 that LuxIA, their co-developed artificial intelligence algorithm for diabetic retinopathy screening, had received CE m...
Aldeyra Achieves Primary Endpoint in Phase III Dry Eye Chamber Trial of Reproxalap, Plans NDA Resubmission
Aldeyra Therapeutics reported May 5 that topical reproxalap achieved the primary endpoint of statistically significant improvement in ocular discomfort vs. vehicle in a Phase III dry eye chamber tr...
US FDA Grants RMAT Status to Opus’ LCA5 Gene Therapy Candidate
Opus Genetics announced May 6 that the US FDA had granted regenerative medicine advanced therapy (RMAT) designation to OPGx-LCA5, its investigational gene therapy for the treatment of Leber congeni...
US FDA Grants RMAT Status to 4DMT’s Gene Therapy Candidate in DME
4D Molecular Therapeutics announced May 1 that the US FDA had granted regenerative medicine advanced therapy (RMAT) designation to 4D-150, an intravitreal gene therapy candidate for diabetic macula...
US FDA Extends Luminopia Amblyopia Treatment Clearance to Children Ages 8 to 12
Luminopia announced April 22 that the US FDA had cleared its amblyopia (lazy eye) treatment for patients ages 8 to 12, extending the age range of its existing label. The Luminopia system was grante...
Q1-2025 Ophthalmic Revenue Roundup for Roche, Regeneron, AbbVie, Glaukos, Lumibird, and Biogen
Swiss company Roche reported April 24 that Vabysmo sales in Q1-2025 were CHF 1 billion ($1.1 billion, calculated March 31, 2025), up 18 percent in constant currency from CHF 847 million in Q1-2024....
New Laws in Montana, West Virginia Expand ODs’ Scope to Include Laser
Montana and West Virginia became the 13th and 14th US states, respectively, to pass laws expanding optometrists’ scope of practice to include in-office laser procedures. West Virginia’s measure spe...
Formosa Licenses Clobetasol Propionate Drops to Chile’s Saval for Latin America
Taiwan-based Formosa Pharmaceuticals announced April 25 that it had agreed to license to Chile’s Laboratorios Saval exclusive rights to market clobetasol propionate 0.05% eye drops for postsurgical...
NanoDrops Names Daria Lemann-Blumenthal as CEO
Israel’s NanoDrops announced April 22 that it had appointed Belkin Vision co-founder Daria Lemann-Blumenthal as its new chief executive officer. NanoDrops, founded in 2020, employs a laser-etched p...
Allotex Ramps Up Commercialization of Presbyopia Implant, Appoints Michael Mrochen, PhD, as CEO
Allotex announced April 23 the acceleration of commercialization of its human collagen-based corneal implant for presbyopia—along with the appointment of company co-founder Michael Mrochen, PhD, as...
Want to Read the Full Article?
Already Have an Account?
Register A Corporate Account
A corporate account gives you access to licensed reports and subscriptions, the latest news, a personalized dashboard, and weekly emails with news and data.